study of Oxytocin versus Carbetocin for the prevention of primary post partum hemorrhage following caesarean delivery in pregnant wome
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: O80-O82- Encounter for delivery
- Registration Number
- CTRI/2024/04/065815
- Lead Sponsor
- self
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
female with singleton, fullterm pregnancy undergoing elective or emergency caesarean section,
Exclusion Criteria
Hypersensitivity to study drugs,
Cases of coagulopathy,uterine fibroid,suspected placental pathology,
Medical diseases such as hypertension,diabetes mellitus,Cardiac ,renal,liver disorders .
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of hemodynamic effects of carbetocin in terms of blood loss.Timepoint: 24 hours after ceserean section
- Secondary Outcome Measures
Name Time Method 1.Need of additional uterotonics <br/ ><br>2.Need of blood transfusion to compensate the blood loss. <br/ ><br>3.The adverse effects encountered by the participants.Timepoint: 24 hours after ceserean section
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Oxytocin and Carbetocin prevent primary postpartum hemorrhage following caesarean delivery?
How does the efficacy of Carbetocin compare to Oxytocin as a standard-of-care for preventing postpartum hemorrhage in caesarean deliveries?
Are there specific biomarkers that can predict which patients will respond better to Oxytocin or Carbetocin in postpartum hemorrhage prevention?
What are the known adverse events associated with Oxytocin versus Carbetocin in caesarean delivery settings and how are they managed?
What other uterotonic agents or combination therapies are being explored for primary postpartum hemorrhage prevention alongside Oxytocin and Carbetocin?